THIS CALL FOR ABSTRACTS IS ONLY FOR INDUSTRY/PHARMACEUTICAL COMPANIES!

The 5th World Congress of Cutaneous Lymphomas will take place on April 11-13, 2024, in California, USA at the Pasadena Convention Center. This Congress will highlight high-impact contributions to the management and investigation of cutaneous lymphomas. The Scientific Committee invites you to submit your abstracts in this field for Poster consideration. Abstract acceptance will be driven by scientific merit, where only the best submissions will be selected. 

SUBMIT YOUR SCIENTIFIC RESEARCH

As you prepare for your abstract submission, please make sure to review the Abstract Reference Guidelines below and make note of the following details:

• Abstracts may ONLY be submitted online.
• There are no restrictions on the number of abstracts you may submit.
• 500 word limit for body of Abstract
• No submission extensions will be granted.

AUTHOR & SUBMISSION ELIGIBILITY

As you prepare for your abstract submission, please make note of the following eligibility criteria:

• These submissions are only from authors and/or co-authors who are employees of pharmaceutical, biotechnology, or medical technology companies.
• Authors of all accepted abstracts are expected to present at the Congress, and therefore, must pay the registration fee to attend. 
• If author of accepted abstract is not from a company that is exhibiting/sponsoring the Congress, in addition to paying the attendee registration fee, the author of selected abstract will have to pay a $1,500 "Presenter" fee.

ABSTRACT SELECTION PROCESS & PRESENTATIONS

All abstracts are subject to an anonymized peer-review by members of the 5th World Congress of Cutaneous Lymphomas Scientific Committee. 

CALL FOR ABSTRACTS REFERENCE GUIDE

ABSTRACT SUBMISSION REQUIREMENTS

As you prepare for your abstract submission, please make note of the following requirements and instructions.

Word Limit: There is a limit of 500 words for abstract body submission. 

Title: The title should be entered in mixed case (upper and lower-case letters). DO NOT enter the title in all capital or all lower-case letters. Abbreviations may not be used in the title, unless it follows the full name.

Abstract Body:

Include the following:

TRIALS IN PROGRESS

GUIDELINES:

• All phases of clinical research (Phases I to III, Supportive Care, nonpharmacological Interventions) may be submitted. 
• Trials must be ongoing, and as a result should not have reached pre-specified endpoints.
  Early results/preliminary data is allowed, rather than noting “Significant Results”, therefore, reporting on “Trial Status” is allowed.

INTRODUCTION: The introduction should be 2 or 3 brief sentences describing the scientific background/rationale for the trial.

METHODS: A description of the methods used to conduct the trial must be included (i.e., Trial design and statistical methods, planned treatment, eligibility criteria, current enrollment). 

TRIAL STATUS: Provide 2 or 3 brief sentences reporting on the trial status. 
Allowable Information:
Phase I: Phase, Cohorts completed without DLT, Month & Year of when enrollment in current cohort began.
Phase II: How many of the specific number of planned patients have been enrolled, or if prespecified activity goals of the accrual stage were met, Month & Year of when current stage accrual began.
Phase III:  Month & Year the DMC last reviewed the trial, and suggestions that resulted from the review.
Required Information: List the clinical trials.gov number.

CONCLUSION: The conclusion should be no more than 2 or 3 sentences regarding the significance of the trial, highlighting the potential transition of new agents into the clinic. 

Questions to address in the abstract:

1. Why was the trial conducted/case reported?

2. How was the trial conducted/case reported?

3. What is the status of the trial?

4. What is the significance of the trial?

Table or Image: You may add one table OR one image to your abstract (not both). Characters will not be deducted from the total character count for tables and images. 

COMMON REASONS ABSTRACTS ARE REFUSED

• Too little data
• Abstract did not conform to guidelines
• Author or Institution mentioned in body or title
• Conclusion is questionable in relationship to data presented
• Clinical trials.gov number not included.
• Significant data provided, i.e. providing results or endpoints.

ABSTRACT NOTIFICATIONS

Each abstract submitter will receive an acknowledgment of receipt of the abstract after completing a submission. If the abstract is selected for inclusion in the 5th World Congress of Cutaneous Lymphomas, the presenting author listed will receive an invitation to participate in the Congress from the Scientific Committee. If the abstract is not selected, the submitting author will receive a communication regarding its decision. If a first author/presenter chooses to withdraw his or her abstract for any reason, a request must be submitted by February 16, 2024.